WEE1 and diffuse large B-cell lymphoma: For primary investigation we chose WEE1 and PARP1. Although neither of these genes have been investigated in DLBCL in combination with rituximab, both WEE1 and PARP1 have clinically approved inhibiting drugs and have been studied extensively in vivo.